| Overview |
| bs-6043R-RBITC |
| NBL1 Polyclonal Antibody, RBITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NBL1/DAND1 |
| 75-180/180 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4681 |
| Secreted |
| DAN domain family member 1; DAN antibody DAND 1; DAND1; Dferential screening selected gene aberrant in neuroblastoma; NB antibody NBL 1; Neuroblastoma candidate region suppression of tumorigenicity 1; Neuroblastoma suppression of tumorigenicity 1; Neuroblastoma suppressor of tumorigenicity 1; NO 3; NO3; Zinc finger protein DAN. |
| NBL1 (Neuroblastoma, suppression of tumorigenicity 1) is a candidate tumor suppressor of neuroblastoma and may play a role in preventing cells from entering the final stage (G1/S) of the transformation process. NBL1 is a member of the evolutionarily conserved CAN (Cerberus and DAN) family of proteins, which contain a domain resembling the CTCK (C-terminal cystine knot-like) motif found in a number of signaling molecules. It is a member of a class of glycoproteins shown to be secreted inhibitors of the transforming growth factor-beta (TGF-beta) and bone morphogenic protein pathways. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz